Neither Branded Nor Generic Lopinavir/Ritonavir Produces Adequate Lopinavir Concentrations at a Reduced Dose of 200/50 mg Twice Daily

We assessed pharmacokinetic (PK) parameters of reduced dose lopinavir/ritonavir (LPV/r) and compared generic and branded tablets. Twenty HIV-infected patients using protease inhibitors with HIV RNA

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2012, Vol.59 (1), p.55-58
Hauptverfasser:	RAMAUTARSING, Reshmie A, VAN DER LUGT, Jasper, AVIHINGSANON, Anchalee, GOROWARA, Meena, WONGSABUT, Jiratchaya, KHONGPETCH, Chuleeporn, PHANUPHAK, Praphan, ANANWORANICH, Jintanat, LANGE, Joep M. A, BURGER, David M, RUXRUNGTHAM, Kiat
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult AIDS/HIV Anti-HIV Agents - administration & dosage Anti-HIV Agents - pharmacokinetics Antiretroviral drugs Biological and medical sciences Cross-Over Studies Dose-Response Relationship, Drug Female Fundamental and applied biological sciences. Psychology HIV HIV Infections - drug therapy HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - pharmacokinetics HIV Protease Inhibitors - therapeutic use Human immunodeficiency virus Human viral diseases Humans Infectious diseases Lopinavir - administration & dosage Lopinavir - blood Lopinavir - pharmacokinetics Lopinavir - therapeutic use Male Medical sciences Microbiology Middle Aged Miscellaneous Plasma Protease inhibitors Ribonucleic acid Ritonavir - administration & dosage Ritonavir - pharmacokinetics Ritonavir - therapeutic use RNA Therapeutic Equivalency Viral diseases Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We assessed pharmacokinetic (PK) parameters of reduced dose lopinavir/ritonavir (LPV/r) and compared generic and branded tablets. Twenty HIV-infected patients using protease inhibitors with HIV RNA
ISSN:	1525-4135 1944-7884
DOI:	10.1097/qai.0b013e31823ba736